<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02305290</url>
  </required_header>
  <id_info>
    <org_study_id>HREC2014/7/4.6 (4033)</org_study_id>
    <nct_id>NCT02305290</nct_id>
  </id_info>
  <brief_title>Upper GI Outcomes Following EMR</brief_title>
  <acronym>UGI-EMR</acronym>
  <official_title>Outcomes of Endoscopic Resection in the Upper Gastrointestinal Tract</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Professor Michael Bourke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Western Sydney Local Health District</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the long-term outcomes of Endoscopic Resection (ER)&#xD;
      of superficial lesions of the Upper Gastrointestinal Tract(UGIT)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endoscopic resection (ER) of superficial lesions of the upper gastrointestinal tract is a&#xD;
      safe and effective surgery-sparing modality in experienced hands. It is often curative of&#xD;
      dysplastic lesions and is associated with minimal complications and high patient acceptance&#xD;
      (1-5). Westmead Hospital has accumulated a significant amount of experience in the removal of&#xD;
      such lesions; however, there is limited research to document the long term outcomes of&#xD;
      patients undergoing endoscopic resection.The purpose of this study is to evaluate the&#xD;
      long-term outcomes of ER of superficial lesions of the UGIT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2014</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Observed procedural data</measure>
    <time_frame>14 days</time_frame>
    <description>Number of Participants with Adverse Events as a Measure of Safety and Tolerability Outcomes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analysis of the costs of this procedure compared to previous treatments</measure>
    <time_frame>14 days</time_frame>
    <description>Perform cost-utility analyses comparing different treatment approaches for UGIT lesions</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Adenoma, Villous</condition>
  <arm_group>
    <arm_group_label>Endoscopic Mucosal Resection</arm_group_label>
    <description>Patients who are referred for Endoscopic Mucosal Resection of Upper Gastrointestinal Lesions will be included in this cohort.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic Mucosal Resection</intervention_name>
    <arm_group_label>Endoscopic Mucosal Resection</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who have Upper Gastrointestinal Tract adenomas which are amendable to Endoscopic&#xD;
        Mucosal Resection&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  UGIT lesion &gt; 10mm&#xD;
&#xD;
          -  Lesion limited to the mucosal and/or submucosal layer (T1 lesion)&#xD;
&#xD;
          -  Aged 18 years or older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lesion less than 10mm&#xD;
&#xD;
          -  Gastric lesion involves the muscularis propria (T2 lesion) on other staging modalities&#xD;
             such as endoscopic ultrasonography (EUS)&#xD;
&#xD;
          -  Aged younger than 18 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael J Bourke, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Western Sydney Local Health District</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rebecca Sonson, BN</last_name>
    <phone>98455555</phone>
    <phone_ext>59779</phone_ext>
    <email>kathleen.goodrick@health.nsw.gov.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>Westmead Endoscopy Unit</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Sonson, BN</last_name>
      <phone>98455555</phone>
      <phone_ext>59779</phone_ext>
      <email>Kathleen.goodrick@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Michael J Bourke, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephen J Williams, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Farzan F Bahin, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 30, 2014</study_first_submitted>
  <study_first_submitted_qc>November 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2014</study_first_posted>
  <last_update_submitted>March 21, 2021</last_update_submitted>
  <last_update_submitted_qc>March 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Western Sydney Local Health District</investigator_affiliation>
    <investigator_full_name>Professor Michael Bourke</investigator_full_name>
    <investigator_title>Director of Gastrointestinal Endoscopy</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Adenoma, Villous</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

